Clinical impact of sarcopenia in patients with uterine cervical cancer treated with radiotherapy

Objective: Though sarcopenia is known to be associated with worse prognosis in various tumors, studies regarding the significance of sarcopenia in uterine cervical cancer are uncommon. We investigated the clinical impact of sarcopenia in patients with uterine cervical cancer treated with radiotherapy (RT). Methods: Among 104 patients who received RT for uterine cervical cancer between 2011 and 2018, 58 patients treated with a definitive or adjuvant aim were included in this study. Sarcopenia was determined by measuring the skeletal muscle area using computed tomography that was performed for RT planning. Results: Among the 58 patients, 30 patients (51.7%) had sarcopenia and 20 patients (66.7%) with sarcopenia had a normal body mass index (BMI). The median age of patients was 55.5 years. There was no linear relationship between age and prevalence of sarcopenia. During the median follow-up period of 35 months, 3 patients died and 11 patients had disease recurrence or progression. Sarcopenia was associated with a worse progression-free survival (PFS; HR 12.301, 95% CI 2.243–67.450, p = 0.004). The 2-year PFS rates of patients with and without sarcopenia were 66.3% and 92.3%, respectively (p = 0.008). Conclusions: Sarcopenia was observed in approximately half of the patients who received RT for cervical cancer, including patients with a normal BMI. Sarcopenia was associated with a worse PFS, and treatment interruption or discontinuation was more frequent among patients with sarcopenia. Evaluation of skeletal muscle mass and support to reduce skeletal muscle loss could be useful to optimize treatment and achieve better PFS.

Sarcopenia; Cervical cancer; Radiotherapy; Survival

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018; 68: 394–424.

[2] Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019; 48: 601–601.

[3] Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Applied Physiology, Nutrition, and Metabolism. 2008; 33: 997–1006.

[4] Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. European Journal of Cancer. 2016; 57: 58– 67.

[5] Antoun S, Borget I, Lanoy E. Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Current Opinion in Supportive & Palliative Care. 2013; 7: 383– 389.

[6] Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecology & Obstetrics. 2019; 145: 129–135.

[7] Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecologic Oncology. 1999; 73: 177–183.

[8] Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. International Journal of Radiation Oncology, Biology, Physics. 2006; 65: 169–176.

[9] Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Journal of Clinical Oncology. 2000; 18: 1606–1613.

[10] Sottier D, Petit J, Guiu S, Hamza S, Benhamiche H, Hillon P, et al. Quantification of the visceral and subcutaneous fat by computed tomography: interobserver correlation of a single slice technique. Diagnostic and Interventional Imaging. 2013; 94: 879–884.

[11] Chen L, Liu L, Woo J, Assantachai P, Auyeung T, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. Journal of the American Medical Directors Association. 2014; 15: 95–101.

[12] Matsuoka H, Nakamura K, Matsubara Y, Ida N, Nishida T, Ogawa C, et al. Sarcopenia is not a prognostic factor of outcome in patients with cervical cancer undergoing concurrent chemoradiotherapy or radiotherapy. Anticancer Research. 2019; 39: 933–939.

[13] Lee J, Chang C, Lin J, Wu M, Sun F, Jan Y, et al. Skeletal muscle loss is an imaging biomarker of outcome after definitive chemoradio-therapy for locally advanced cervical cancer. Clinical Cancer Research. 2018; 24: 5028–5036.

[14] Kiyotoki T, Nakamura K, Haraga J, Omichi C, Ida N, Saijo M, et al. Sarcopenia is an important prognostic factor in patients with cervical cancer undergoing concurrent chemoradiotherapy. International Journal of Gynecologic Cancer. 2018; 28: 168–175.

[15] Awad S, Tan BH, Cui H, Bhalla A, Fearon KCH, Parsons SL, et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clinical Nutrition. 2012; 31: 74–77.

[16] Stene GB, Helbostad JL, Amundsen T, Sørhaug S, Hjelde H, Kaasa S, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncologica. 2015; 54: 340–348.

[17] Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MAE, den Braver NR, Berkhof J, Langius JAE, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2016; 34: 1339–1344.

[18] Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. Journal of the American Medical Directors Association. 2011; 12: 249–256.

[19] Silva AM, Shen W, Heo M, Gallagher D, Wang Z, Sardinha LB, et al. Ethnicity-related skeletal muscle differences across the lifespan. American Journal of Human Biology. 2010; 22: 76–82.

[20] Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Annals of Oncology. 2017; 28: 2107–2118.

[21] Ganju RG, Morse R, Hoover A, TenNapel M, Lominska CE. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiotherapy and Oncology. 2019; 137: 117–124.

[22] Cho Y, Kim JW, Keum KC, Lee CG, Jeung HC, Lee IJ. Prognostic significance of sarcopenia with inflammation in patients with head and neck cancer who underwent definitive chemoradiotherapy. Frontiers in Oncology. 2018; 8: 457.

[23] Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. International Journal of Radiation Oncology Biology Physics. 1995; 32: 1275–1288.

[24] Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervix cancer. Radiotherapy and Oncology. 1992; 25: 273–279.

[25] Girinsky T, Rey A, Roche B, Haie C, Gerbaulet A, Randrianarivello H, et al. Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. International Journal of Radiation Oncology, Biology, Physics. 1993; 27: 1051– 1056.

[26] Cybulska P, Goss C, Tew WP, Parameswaran R, Sonoda Y. Indications for and complications of transfusion and the management of gynecologic malignancies. Gynecologic Oncology. 2017; 146: 416–426.

[27] Chen S, Tao M, Zhao L, Zhang X. The association between diabetes/hyperglycemia and the prognosis of cervical cancer patients: a systematic review and meta-analysis. Medicine. 2017; 96: e7981.

[28] Rivard C, Stockwell E, Yuan J, Isaksson Vogel R, Geller MA. Age as a prognostic factor in cervical cancer: a 10-year review of patients treated at a single institution. Gynecologic Oncology. 2016; 141: 102.

[29] Ethier J, Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecologic Oncology. 2017; 145: 584–594.

[30] Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. International Journal of Radiation Oncology, Biology, Physics. 2005; 63: 25–36.

[31] Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. British Journal of Cancer Supplement. 1978; 3: 302–306.

[32] Thomas G, Ali S, Hoebers FJP, Darcy KM, Rodgers WH, Patel M, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above

10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecologic Oncology. 2008; 108: 317–325.

[33] Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options—a mini-review. Gerontology. 2014; 60: 294–305.

[34] Davis MP, Panikkar R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Annals of Palliative Medicine. 2019; 8: 86–101.

[35] Dunne RF, Loh KP, Williams GR, Jatoi A, Mustian KM, Mohile SG. Cachexia and sarcopenia in older adults with cancer: a comprehensive review. Cancers. 2019; 11: 1861.